B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42

Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res (2009) 2.36

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11

FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. Cancer Res (2010) 1.39

Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.38

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ (2012) 1.24

c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia (2010) 1.20

Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19

Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm (2011) 1.17

B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene (2011) 1.10

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J Biol Chem (2012) 1.01

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene (2015) 0.98

Critical role of STAT3 in melanoma metastasis through anoikis resistance. Oncotarget (2014) 0.98

Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell (2008) 0.97

Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications. PLoS One (2009) 0.89

C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One (2011) 0.88

Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials (2014) 0.86

Acquisition of anoikis resistance through CD147 upregulation: A new mechanism underlying metastasis of hepatocellular carcinoma cells. Oncol Lett (2012) 0.86

Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85

Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol (2009) 0.85

Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol (2007) 0.83

AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells. PLoS One (2014) 0.83

Anoikis mediators in oral squamous cell carcinoma. Oral Dis (2010) 0.81

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Res (2015) 0.81

TGF-beta has paradoxical and context dependent effects on proliferation and anoikis in human colorectal cancer cell lines. Growth Factors (2008) 0.81

Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res (2012) 0.80

ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis (2012) 0.79

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther (2017) 0.75

Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75

Integrin signaling and cell growth control. Curr Opin Cell Biol (1998) 3.32

Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene (2008) 1.79

Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J Cell Biol (1997) 1.78

Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene (2010) 1.57

Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene (2006) 1.28

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ (2012) 1.24

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene (2011) 1.10

Integrin regulation of receptor tyrosine kinase and G protein-coupled receptor signaling to mitogen-activated protein kinases. Methods Enzymol (2001) 0.81

ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis (2012) 0.79